Rexahn Pharmaceuticals, Inc.  

(Public, NYSEMKT:RNN)   Watch this stock  
Find more results for NYSEAMEX:RNN
+0.009 (1.74%)
Oct 9 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.50 - 0.51
52 week 0.48 - 0.95
Open 0.50
Vol / Avg. 181,196.00/365,509.00
Mkt cap 91.90M
P/E     -
Div/yield     -
EPS -0.06
Shares 180.70M
Beta 0.44
Inst. own 5%
Nov 11, 2015
Q3 2015 Rexahn Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Sep 16, 2015
Rexahn Pharmaceuticals Inc at EBD Group BioPharm America
Sep 10, 2015
Rexahn Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
Aug 10, 2015
Q2 2015 Rexahn Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -44.85% -69.77%
Return on average equity -57.90% -94.48%
Employees 22 -
CDP Score - -


Suite 455, 15245 Shady Grove Road
United States - Map
+1-240-2685300 (Phone)
+1-240-2685310 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of treatments for cancer and other medical needs. The Company has three clinical stage drug candidates in active development: Archexin, a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance; RX-3117, a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including colon, lung and pancreatic cancer, and Supinoxin (RX-5902), a small molecule that inhibits the phosphorylation of p68, which is expressed in cancer cells, but not in normal cells, results in up-regulation of cancer-related genes and a subsequent proliferation or tumor growth of cancer cells. The Company also has two drug candidates in pre-clinical development: Archexin-Nano and RX-21101.

Officers and directors

Peter C. Brandt Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Chang H. Ahn Chairman Emeritus, Chief Scientist
Age: 63
Bio & Compensation  - Reuters
Peter D. Suzdak Ph.D. Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Tae Heum Jeong Chief Financial Officer, Secretary
Age: 44
Bio & Compensation  - Reuters
Ely Benaim Chief Marketing Officer
Age: 54
Bio & Compensation  - Reuters
Charles G. Beever Independent Director
Age: 62
Bio & Compensation  - Reuters
Mark P. Carthy Independent Director
Age: 54
Bio & Compensation  - Reuters
Kwang Soo Cheong Independent Director
Age: 54
Bio & Compensation  - Reuters
Richard J. Rodgers Independent Director
Age: 48
Bio & Compensation  - Reuters